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| INVESTIGATION
Functional Redundancy of DICER Cofactors TARBP2
and PRKRA During Murine Embryogenesis Does Not
Involve miRNA Biogenesis
Sri Ramulu N. Pullagura,*,† Bill Buaas,* Nichelle Gray,* Lindsey C. Krening,* Anuj Srivastava,*
and Robert E. Braun*,†,1
*The Jackson Laboratory, Bar Harbor, Maine 04609 and †Graduate School of Biomedical Sciences and Engineering, The University
of Maine, Orono, Maine 04469
ABSTRACT Several in vitro studies have suggested that canonical microRNA (miRNA) biogenesis requires the DICER cofactors TARBP2
and PRKRA for processing of pre-miRNAs to mature miRNAs. To investigate the roles of TARBP2 and PRKRA in miRNA biogenesis in vivo,
and to determine possible functional redundancy, we first compared the phenotypes of Tarbp2 and Prkra single and double mutants. In
contrast to Dicer 2/2 embryos, which die by embryonic day 7.5 (E7.5), single Tarbp2 2/2 and Prkra 2/2mice survive beyond E7.5 and either
die perinatally or survive and exhibit cranial/facial abnormalities, respectively. In contrast, only a few Tarbp2 2/2; Prkra 2/2 double mutants
survived beyond E12.5, suggesting genetic redundancy between Tarbp2 and Prkra during embryonic development. Sequencing of miRNAs
from single-mutant embryos at E15.5 revealed changes in abundance and isomiR type in Tarbp2 2/2, but not Prkra 2/2, embryos,
demonstrating that TARBP2, but not PRKRA, functions in miRNA biogenesis of a subclass of miRNAs, and suggesting that functional
redundancy between TARBP2 and PRKRA does not involve miRNA biogenesis.
KEYWORDS TARBP2; PRKRA; PACT; DICER; miRNA
MICRORNAS (miRNAs) are a large family of endoge-nously encoded 22 nucleotide (nt) noncoding RNAs
that modulate post-transcriptional gene regulation through
translational control and thedecayofmessengerRNAs (mRNAs)
(Krol et al. 2010). Target specificity of a miRNA is conferred by
the seed sequence, which comprises nucleotides 2–8 of the
22-nt small RNA (Lewis et al. 2003, 2005; Doench and Sharp
2004; Grimson et al. 2007; Wee et al. 2012). Extensive base
pairing of the miRNA seed sequence to the target mRNA leads
to translational repression and mRNA degradation, with 50%
of all protein-coding genes predicted to be miRNA targets (Baek
et al. 2008; Selbach et al. 2008; Friedman et al. 2009). The
human genome is estimated to encode 1900 miRNA genes,
with many exhibiting developmental and stage-specific expres-
sion patterns (Landgraf et al. 2007; Griffiths-Jones et al. 2008).
Mammalian DICER is the principal cytoplasmic enzyme that
generates miRNAs and, in association with its double-stranded
RNA-Binding Protein (dsRBP) cofactors TARBP2 and PRKRA,
binds the70-nt-long pre-miRNA “hairpin” and cleaves the loop
to produce a double-stranded RNA (dsRNA) duplex (Bernstein
et al. 2001; Grishok et al. 2001; Hutvagner et al. 2001; Ketting
et al. 2001; Knight and Bass 2001; Chendrimada et al. 2005;
Haase et al. 2005; Lee et al. 2006; Kok et al. 2007; Koscianska
et al. 2011). The fully processed duplex RNA is loaded into the
RNA-induced silencing complex (RISC), where one strand is
degraded leaving the guide strand (Kawamata and Tomari
2010). In TARBP2, the double-stranded RNA-binding domain
(dsRBD)motif is present in two copies along with a C-terminal
protein–protein “Medipal” interaction domain that binds
DICER (Lee et al. 2004; Laraki et al. 2008; Daniels et al.
2009). Several in vitro studies have shown that the DICER-
TARBP2 complex exhibits ATP-independent dynamic diffusion
along the length of pre-miRNA until it encounters a hairpin
structure, which determines the site of cleavage by DICER
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(Koh et al. 2012, 2017; Wilson et al. 2015). Prkra is the only
mammalian Tarbp2 paralog and encodes a protein with high
sequence similarity and structure to TARBP2. Like TARBP2,
PRKRA contains two dsRBDs and a C-terminal Medipal do-
main that interacts with DICER (Laraki et al. 2008; Daniels
and Gatignol 2012). In vitro biochemical and cell culture
experiments suggest that loss of the DICER cofactors TARBP2
and PRKRA disrupts pre-miRNA processing, RISC loading of
miRNAs, and RNA interference (RNAi) activity (Chendrimada
et al. 2005; Haase et al. 2005; Chakravarthy et al. 2010; Daniels
and Gatignol 2012). Apart from miRNA biogenesis, TARBP2 is
reported to bind dsRNA directly and destabilize it (Goodarzi
et al. 2014), whereas PRKRA regulates translation by activat-
ing protein kinase (PKR) (Daniels andGatignol 2012), a global
inhibitor of translation. TARBP2 also promotes translation by
binding and inhibiting PKR during human immunodeficiency
virus infection, thereby assisting in viral replication (Daniels
and Gatignol 2012).
Maternally supplied Dicer mRNA is expressed in murine
oocytes, reaching its highest levels in germinal vesicle-stage
oocytes, and then falling to its lowest detectable level in
eight-cell-stage embryos (Murchison et al. 2007). Condi-
tional ablation of Dicer in oocytes using Zp3Cre results arrest
in meiosis I as a consequence of spindle dysfunction and defects
in chromosome congression (Murchison et al. 2007; Tang et al.
2007). Loss of zygoticDicermRNA,which normally begins to be
expressed in blastocyst-stage embryos (Murchison et al. 2007),
leads to early developmental defects and embryonic arrest
shortly after gastrulation around embryonic day 7.5 (E7.5)
(Bernstein et al. 2003). Furthermore, conditional gene targeting
has revealed that DICER functions in the development or homeo-
stasis of embryonic and fetal organs including the cardiovascular,
genitourinary, musculoskeletal, and nervous systems (Bernstein
et al. 2003; O’Rourke et al. 2007; Saal and Harvey 2009; Zehir
et al. 2010; Small and Olson 2011). These data are consistent
with amodelwheremiRNAs function in the proper development
of numerous mammalian organs, and disruptions in this small
RNA biogenesis pathway can result in congenital birth defects
and in extreme cases fetal death. The mouse Tarbp2 gene en-
codes a 365-amino acid protein that is localized predominantly
to the cytoplasm, and Tarbp2 2/2mice on a hybrid background
are viable but have reduced body size and are male sterile
(Zhong et al.1999). Previously characterizedPrkramutantmice
arehomozygousviablewithcranial/facialdefects (Rowe etal.2006;
Dickerman et al. 2011) and, like Tarbp2mutants, exhibit postnatal
growth retardation on several genetic backgrounds, including
C57BL/6J. The similar but different phenotypes of Tarbp2 2/2




Tarbp2tm1reb (Zhong et al. 1999) mice were genotyped as
described previously. Genotyping for the Prkra lear1J mice
was carried out as recommend by the Jackson Laboratory
mutant repository.
High-throughput sequencing of fetal small RNAs
E15.5 C57BL/6J-Tarbp2 tm1reb and C57BL/6J-Prkra lear1J em-
bryos were generated through timed mating intercrosses of
heterozygous male and female mutant mice. Embryos were
dissected at 15.5 days postcoitum and the associated yolk
sac was used for genotyping. The developmental stage was
confirmed using Theiler staging criteria for mouse embryo
development. Embryos were decapitated and both body
and head were immediately immersed in RNAlater (Thermo
Fisher). Whole fetuses (head and body) were homogenized
in TRIzol followed by purification of total RNA using a
QIAGEN miRNeasy kit (Valencia, CA). High-throughput se-
quencing libraries containing small noncoding RNAs (e.g.,
miRNAs or Piwi-interacting RNAs) were generated using
1 mg of total RNA and an Illumina TruSeq small RNA library
preparation kit (Illumina, Inc.). Individually barcoded fetal
libraries were pooled and sequenced (100 bp-end reads) on
a single HiSequation 2000 flow cell lane running version
3 chemistry. Illumina CASAVA software was used to carry
out BCL to Fastq conversion. All the samples were passed
through quality control and sequences with poor base quali-
ties were removed. The adaptor sequences were removed
using the clip_adaptors.pl module of mirdeep (v2.0.0.5)
(Friedlander et al. 2012). Raw reads were collapsed based
on sequence identity using the collapse_reads_md.pl module
of mirdeep2. Collapsed reads were further annotated for
miRNA by mapping to miRBase version 21 (Griffiths-Jones
et al. 2008; Kozomara and Griffiths-Jones 2011; Friedlander
et al. 2012) using the miraligner module of seqbuster
(Pantano et al. 2010). IsomiRs were identified using the
R isomiRs (v1.3.0) package of seqbuster. Pairwise differential
expression was performed among different groups using
DESEQ2 (v1.12.4) (Love et al. 2014).
Quantitative RT-PCR and Taqman assays
Adult tissues were used for total RNA extraction (TRIzol;
Invitrogen, Carlsbad, CA), followed by the production of
random primed cDNA (18080051; Invitrogen). Real-time
PCR using SYBR green (ABI 7500; Thermo Fisher) and the
ddCT method for calculating relative gene expression were
used to determine Prkra and Tarbp2 transcript levels. b-actin
amplification was used as an endogenous control. For miRNA
Taqman assays, total RNA is extracted (TRIzol extraction;
Invitrogen) from transformed mouse embryonic fibroblasts
(MEFs), followed by production of cDNA specific to each
miRNA (4427975; Thermo Fisher) using a Taqman miRNA
reverse transcription kit (4366596; Thermo Fischer). Taq-
man PCR using Taqman Universal Master Mix II (4440042;
Thermo Fisher) and the ddCT method for calculating rela-
tive transcript expression were used to determine mature
miRNA levels. U6 amplification was used as an endogenous
control.
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Western blotting
PRKRA and TARBP2 protein levels were assayed from the
tissues andMEFs using standardwestern blotting protocols. A
rabbit monoclonal antibody raised against a synthetic pep-
tide corresponding to the C-terminal end of human PRKRA
(#ab75749; Abcam) and a TARBP2 antibody from a previous
study (Zhong et al. 1999) were used to quantify protein lev-
els. GAPDH was used as a loading control.
Cell culture, transformation, and cell number calculation
MEFs were isolated at E11.5 and transformed by infecting
with viral supernatant from simian virus 40 (SV40) T antigen
(pBABE SV40 T antigen from Addgene #13970)-packaged
cells (Plat-E ecotropic packaging). To obtain stably trans-
fected clones, cells were selected with 2 mg/ml puromycin
and single clones were isolated using clonal rings. Trans-
formed MEFs were cultured in Dulbecco’s modified Eagle’s
medium (DMEM containing high glucose level; GIBCO
[Grand Island Biological], Grand Island, NY) supplemented
with 10% fetal bovine serum (Invitrogen). For cell number
quantification, transformed MEFs were seeded at an initial
density of 1 3 105 cells/well on the day prior to treatment
with 40 mg/ml DMSO, enoxacin, and incubated at 37 in
5% CO2. The cell numbers were calculated on day 0, day 3,
and day 5 using trypan blue staining and a Countess cell
counter.
Embryo dissection and b-gal staining
Timedmatingswere setup tocollect theembryosvarying from
embryonic day E8.5 to E13.5. Embryo genotypes were de-
terminedbyPCRfromyolk sacDNA.Embryoswerefixed in4%
paraformaldehyde and stained overnight in 5-bromo-4-
chloro-3-indolyl–D-galactoside-containing solution to visu-
alize b-galactosidase activity derived from the lacZ gene
tag in the Tarbp2-targeted mutation. For tissue sections,
embryos were frozen in optimum cutting temperature
(OCT) compound (Sakura Finetek USA Inc.) and cryostat
sectioned. Sections were fixed (0.2% gluteraldehyde) and
stained as above. Sections were postfixed, counterstained
with Nuclear Fast Red, mounted, and imaged under an
Olympus Nanozoomer with the desired magnification.
Skeletal staining and histology
For ossified bone and cartilage staining, E15.5 embryos were
processed using an alizarin red/alcian blue standard staining
protocol (Hogan et al. 1994). Embryos collected at E18.5
were fixed for histology in Bouin’s fixative, then paraffin em-
bedded. Next, 10 mm serial sections were processed using
hematoxylin and eosin staining.
Data availability
Strains are available upon request. miRNA sequencing
data has been uploaded to Bioproject ID: PRJNA423238:
Mus musculus. Raw sequence reads are available at the
Sequence Read Archive (SRA): (TaxId: 39442) SRA ID:
SRP127346.
Results
Tarbp2 is broadly expressed during embryonic
development
To determine where Tarbp2 is expressed during embryonic
development, we analyzed b-galactosidase expression in het-
erozygous Tarbp2 tm1reb/+ embryos (herein referred to as
Tarb2 2/+) containing a LacZ insertion that transcriptionally
tags the Tarbp2 gene (Supplemental Material, Figure S1A).
In whole-mount staining of Tarbp2 +/2 embryos, we ob-
served high levels of b-galactosidase activity throughout all
stages of development, as early as E8.5 whenDicer is expressed
(Figure S1B). In sections of E13.5 organs, we detected expres-
sion in some, but not all, cells in the heart, hindbrain, and liver
(Figure S1C). This organ expression was confirmed by RT-PCR
analysis of Tarbp2 in wild-type E13.5 extracts (Figure S1C).
Tarbp2 is expressed in all adult mouse tissues, with abundant
transcript levels in the testis, although expression is restricted by
cell type (Zhong et al. 1999). Thus, mouse Tarbp2 is broadly
expressed from early embryonic stages through to adulthood
with likely cell type-specific expression in many, if not all,
tissues.
Tarbp2 null animals are smaller but exhibit no gross
anatomical defects
Previously, we reported a smaller body size, early postnatal
lethality, and male sterility in Tarbp2 2/2 mice on a mixed
genetic background (Zhong et al. 1999). To determine if
early defects in ossification could explain the size difference
in mutant animals, we stained E15.5 embryos with alizaran
red/alcian blue to mark bone and cartilage, respectively.
Stained embryos were smaller than control littermates (Fig-
ure S1D) with delayed ossification of the tympanic mem-
brane and spinal column. To compare the size of organs
and soft tissues in Tarbp2mutants, we performedmicro com-
puter tomography (microCT) on E15.5 embryos. We ob-
served a 20% decrease in total volume in Tarbp2 mutants
compared to controls (red outline, Figure S1E) but no signif-
icant relative difference in the size of any single organ or
tissue. We conclude that growth retardation defects begin
in utero, as early as E15.5.
The Tarbp2 null allele is embryonic lethal on the C57BL/6J
mouse strain
Tarbp2 2/2 mice have reduced body mass and perinatal le-
thality on a mixed strain background (Zhong et al. 1999).
Because the genetic background can impact phenotypic var-
iation, we tested whether strain background had an effect on
the phenotypes observed in Tarbp2 mutants, and therefore
compared the frequency of observed homozygotes on the
129S4 (129) background to the C57BL/6J (B6) background.
In heterozygous (het)3 het breeding crosses in the 129 back-
ground, we observed a significant reduction in the number of
Tarbp2 2/2 homozygotes at P21, suggesting reduced viability
on the 129 background (Table 1). Tarbp2 2/2mutants on the
B6 genetic background exhibited an even more extreme
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phenotype. In het 3 het crosses, we were unable to recover
any homozygous animals at P14. Furthermore, at E17.5, we
observed only 13% of the expected 25% homozygous ani-
mals. In crosses between 129 Tarbp2 +/2 females and B6
Tarbp2 +/2 males, we observed the expected Mendelian ra-
tios at P21, suggesting that the 129 genetic background has
one or more modifiers that can suppress the lethality ob-
served on the B6 background.
Prkra1J mutants are viable with anatomical defects
Like TARBP2, PRKRA binds DICER and has been shown to
influence miRNA biogenesis in vitro. To compare the require-
ments for Tarbp2 and Prkra during development, we next
analyzed Prkra mutant mice. Three spontaneous mutant
Prkra alleles (lear, little ear) have arisen in The Jackson Lab-
oratory repository colony, displaying small body size and
reduced ear size. These phenotypes are similar to the pre-
viously characterized Prkra-targeted mutant (Rowe et al.
2006) and chemically induced mutants (Dickerman et al.
2011) that produce a complete PRKRA protein deficiency
or a protein isoform deficient in dsRNA binding, respectively.
The lear1J allele (referred to herein as Prkra 2) contains a
splice donor mutation in intron 5 (Figure S2A). Using
RT-PCRon RNA from E13.5 Prkra 2/2mutant organ extracts,
we found a significant decrease in Prkra expression in heart
and kidney (Figure S2B). Furthermore, immunoblots for
PRKRA protein showed dramatically decreased levels in liver,
lung, kidney, and spleen, with complete loss of protein in the
heart (Figure S2C). Thus, Prkra1J is a strong hypomorphic
or null allele that phenocopies previously characterized spon-
taneous and targeted alleles.
Tarbp2 2/2; Prkra 2/2 double mutants die by midgestation
Because Dicer mutants die by E7.5 (Figure 1A), while
Tarbp2 2/2 mutants die perinatally, and Prkra mutants are
viable but have reduced body size and ear deformities, we
asked whether there might be functional redundancy be-
tween Tarbp2 and Prkra during early embryogenesis. To test
this, we crossed Tarbp2 +/2; Prkra +/2 double heterozygotes
and genotyped animals at birth. We failed to obtain any
Tarbp2 2/2; Prkr 2/2 (B6) animals. We therefore looked at
earlier embryonic time points and recovered one E18.5 dou-
ble mutant that was half-the-size of control littermates and
exhibited severe shortening of the snout (Figure 1C). Addi-
tionally, the heart was smaller and there were open cranial
sutures (data not shown). This animal was able to survive
quite late considering that we were only able to recover one
double mutant out of an expected eight, at E12.5 (Figure 1B,
chi square P , 0.05). To determine if open cranial features
were a hallmark of Prkramutants, and if they are affected by
the Tarbp2 locus, we analyzed cranial morphology using
microCT in 8-week-old animals. We consistently observed
open cranial sutures in Prkra 2/2 mutants, and reduction in
Tarbp2 gene dosage further exacerbated this phenotype, as
exemplified in Tarbp2 2/+; Prkra 2/2mutants (Figure S2D).
These data indicate that the structurally similar dsRBPs,
TARBP2 and PRKRA, genetically interact.
miRNA processing is altered in Tarbp 2/2 but not Prkra 2/2
mutants
The difference in phenotypes between Dicer, Tarbp2, and
Prkra single and double mutants led us to ask whether TARBP2
and PRKRA influenced DICER-mediated miRNA biogenesis
in vivo. We collected total RNA from E15.5 B6 Tarbp2 2/2
and Prkra 2/2 embryos and generated high-throughput se-
quencing libraries of small noncoding RNAs for RNA-sequencing
(RNA-seq). Using a false discovery rate pass of , 0.05, we
found that the expression levels of 74 mature miRNAs were
significantly changed in Tarbp2 2/2 mutants (Figure 2A).
Interestingly, these transcripts were both decreased (n =
46, 62%) and increased (n = 28, 38%), suggesting that
TARBP2 is required for a subpopulation of miRNAs during
this stage of development. Conversely, there was no change
in the expression of miRNAs in Prkra 2/2 embryos (Figure
2B), suggesting that PRKRA has no discernable role inmiRNA
biogenesis during this stage of development.
Biochemical data suggests that the dsRBPs can influence
strand selection of the processed pre-microRNA. As TARBP2
determines the site of cleavage by DICER, and addition or
deletion of a nucleotide can alter the stability of processed
miRNA arms, we compared the overall expression level
changes of 3p-miRNAs and 5p-miRNAs. Significant expres-
sion level changes were observed in both populations; how-
ever, there were more changes to 3p-miRNAs (44 out of 74)
than 5p-miRNAs (30 out of 74) in Tarbp2 2/2 embryos com-
pared to wild-type embryos, suggesting a preferential defect
in processing of 3p-miRNAs in the absence of TARBP2 (Fig-
ure 2C). Also, in Tarbp2 2/2 embryos we observed that there
was an increase in the number of reads mapped to 3p-
miRNAs with an addition (An) or deletion (Dn) of nucleotides
at the 59 end compared to wild-type embryos (Figure 2D),
suggesting an improper cleavage site selection by DICER in
the absence of TARBP2. In Prkra 2/2 mutant embryos, the
level of expression of 3p-miRNAs and 5p-miRNAs remained
the same as in wild-type embryos (Figure 3A), as did the
length of the 3p-miRNAs (Figure 3B). A comparison of the
observed changes in miRNA populations in Tarbp2 2/2 and
Prkra 2/2 mutants is shown in Figure 3C. Because an equal
number of reads were mapped to miRNAs and other small
noncoding RNAs independent of the genotype (Figure 3D),
we conclude that TARBP2 but not PRKRA is required for the
processing of a subclass of miRNAs at E15.5.
Table 1 Background strain dependence of Tarbp2
Strain Age +/+ +/2 2/2
129S4 (129) P21 29 (26%) 66 (58%) 18 (16%)
C57Bl/6J (B6) E17.5 11 (21%) 35 (66%) 7 (13%)
P14 23 (31%) 53 (69%) 0 (0%)
129 3 B6 F1 P21 22 (23%) 51 (53%) 23 (24%)
P, postnatal day; E, embryonic day.
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Pharmacological assessment of the role of TARBP2 and
PRKRA on miRNA processing
In a screen for small molecules that modify RNAi activity, the
synthetic antibacterial compound enoxacin was identified as
an enhancer of RNAi (Shan et al. 2008). Several studies have
reported that enoxacin binds human TARBP2, increases
TARBP2 affinity for pre-miRNAs, and enhances the process-
ing of pre-miRNAs to mature miRNAs (Melo et al. 2011;
Cornaz-Buros et al. 2014). To confirm our findings that
TARBP2, but not PRKRA, is involved in miRNA processing
during embryogenesis, we examined the effect of enoxacin
on the growth ofMEFs derived fromTarpb22/2 and Prkra2/2
mutant embryos. Western blot analysis showed that PRKRA
and TARBP2 were detected in MEFs derived from wild-type
embryos but not Prkra 2/2 or Tarbp2 2/2 mutants, respec-
tively (Figure 4A). To assess whether enoxacin differentially
affected Prkra 2/2 but not Tarbp2 2/2 mutant MEFs, we
treated the cells with DMSO and enoxacin as described pre-
viously (Melo et al. 2011). When cell numbers from day 0,
day 3, and day 5 were plotted comparing DMSO-treated cells
with enoxacin, we observed that Tarbp2 2/2 mutants were
more resistant to enoxacin than wild-type and Prkra 2/2
mutant MEFs at day 3, although by day 5 all genotypes were
similarly affected (Figure 4B and Figure S3). To directly test
the effect of enoxacin on miRNA levels, we measured the
effect of enoxacin on the abundance of 10 miRNAs whose
levels were altered in Tarbp2 2/2 E15.5 embryos. Treatment
of wild-type MEFs with enoxacin significantly decreased the
relative levels of 3/8 miRNAs (Figure 4C top), although none
of the levels of miRNAs were elevated as we had predicted.
The levels of two of the miRNAs, miR-127 and miR145,
remained significantly depressed in Prkra 2/2 MEFs, while
the levels of one miRNA, miR-120, were rescued, although
not to wild-type levels (Figure 4B middle). On the other
hand, mutation of Tarbp2 rescued levels of miR-127 and
miR145 to wild-type levels, but had no effect on miR-120
and actually resulted in an increase in two miRNAs, let-7e
and miR-484, that had been unaffected in wild-type MEFs.
From these observations we conclude that enoxacin does act
solely through TARBP2 and that there is no direct correlation
with the increase in miRNAs and the effect of enoxacin on the
cell growth of transformed MEFs.
Discussion
Previous in vitro studies suggested that TARBP2 and PRKRA
act as cofactors of DICER for the processing of pre-miRNA
to mature-miRNAs. The discordance between the pheno-
types of Dicer1 2/2, Tarbp2 2/2, and Prkra 2/2 single mu-
tants led us to test these findings and to determine if
TARBP2 and PRKRA have redundant functions in miRNA
biogenesis.
Our results strongly suggest that Tarbp2 and Prkra genet-
ically interact during embryonic development. Earlier studies
have established the essentiality of Dicer during oogenesis
and embryogenesis. Maternal Dicer mRNA, which is present
throughout oocyte development (Murchison et al. 2007), is
required for the completion of meiosis 1 (Murchison et al.
2007; Tang et al. 2007), and elimination of zygotic Dicer
expression results in an embryonic lethality phenotype by
E7.5. We failed to recover the expected number of Tarbp2 2/2,
Prkra 2/2 double mutants at E12.5, and recovered only one
double-mutant embryo, which was severely abnormal, at
E18.5. It is possible that the missing embryos died prior to
E7.5, similar to that seen for Dicer2/2 embryos, and that the
few embryos recovered at E12.5 and E18.5 could be due
to incomplete penetrance of the double-mutant phenotype.
Furthermore, we found that the allele status at Tarbp2 af-
fected the closure of cranial sutures observed in Prkra 2/2
mutants.
Figure 1 Tarbp2 2/2;Prkra 2/2 mutants die at
midgestation. (A) An image summarizing the devel-
opmental stages of survival or embryonic lethality
of Dicer 2/2, Tarbp2 2/2, or Prkra 2/2 single mutants
and Tarbp2 2/2; Prkra 2/2 double mutants. (B) Num-
ber of embryonic day (E)12.5 embryos harvested from
crossing Tarbp2 2/+; Prkra 2/+ double heterozygotes.
x2 = 19.283 (8 d.f.), two-tailed P-value = 0.0134. (C)
An E18.5 Tarbp2 2/2;Prkra 2/2 mutant that is signif-
icantly smaller than a Tarbp2 +/2;Prkra +/+ sibling, and
has a shorter snout.
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miRNA sequencing of wild-type and single mutants at
E15.5 revealed that TARBP2, but not PRKRA, is essential
for proper miRNA biogenesis of a set of miRNAs during
embryonic development. We chose to analyze E15.5 embryos
because of the lack of an observable phenotype in single
mutants at that time point and because double-mutant em-
bryoswere absent, suggesting a requirement for bothTARBP2
and PRKRA at that stage. We observed changes in the abun-
dance and length of both 3p and 5p miRNAs in Tarbp2 2/2
mutants, although the extent of aberrant processing of 3p-
miRNAs was greater than for 5p-miRNAs. Our findings for
TARBP2 are supported by a recently published study using
knockout cell lines (Kim et al. 2014). We did not observe
differences in the abundance, sequence, or lengths of miRNAs
in Prkra 2/2mutants, suggesting that PRKRA is not involved in
miRNA biogenesis during murine embryogenesis. However,
given that we were able to detect minor levels of PRKRA in
some tissues (Figure S2), although not in MEFs (Figure 4),
it remains an open possibility that PRKRA is involved in
miRNA biogenesis.
Interestingly, the absence of TARBP2 affected some but
not all miRNAs. Of the 74 miRNAs whose levels were
affected, 28 were increased and 46 were decreased. We do
not know the basis for the selectivity. In addition, because we
usedRNA isolated fromwhole embryos,we donot know if the
affectedmiRNAs are expressed in the same cells or in different
cells. These observations support the hypothesis that DICER
acts independently of TARBP2prior to E7.5, as not allmiRNAs
require TARBP2 for their biogenesis. We also observed a
dependency for TARBP2 on isomiR biogenesis with a bias
towardastronger effect on3p-miRNAs, aspreviously reported
(Wilson et al. 2015). The effect of this change could alter the
half-life or stability of improperly processed mature miRNAs
and ultimately result in the deregulation of RISC complex
formation. Improper targeting of mRNAs by isomiRs could
result in the developmental defects observed in Tarbp2 2/2
animals. The viability of B6129F1 Tarbp2 2/2 hybrids may
also be explained by the restricted effect of the loss of
TARBP2 on miRNA biogenesis. Heterozygosity at miRNA
and target mRNA loci across the genomemay alter the global
miRNA/mRNA profile and suppress the relatively minor
changes in miRNA levels and isomiR types observed in
Tarbp2 2/2 mutants. In support of this, we attempted to
identify quantitative trait loci in the 129 strain that suppress
the lethality and growth defects observed in B6. Assaying for
both viability and body weight, we mapped several loci with
modest LOD scores across the genome that correlated with
one or both phenotypes, indicating that there are multiple
loci that contribute to enhanced survival and body weight in
the F1 hybrid, N2, or mixed backgrounds (Figure S4).
Figure 2 Tarbp2 regulates processing of a subclass
of pre-miRNAs (microRNAs). (A) Plot of miRNA tran-
scripts in Tarbp2 2/2 whole embryos at embryonic
day (E)15.5 and their fold-changes by average ex-
pression using RNA-sequencing (RNA-seq). (B) Plot
of miRNA transcripts in Prkra 2/2 whole embryos at
E15.5 and their fold-changes by average expression
using RNA-seq. (C) Plot of overall expression fold-
change of 3p and 5p miRNA transcripts in C57Bl6
Tarbp2 2/2 whole embryos at E15.5 compared to
wild-type embryos. (D) Plot of 3p arm miRNA tran-
scripts with one, two, or three nucleotide (n = 1, 2,
or 3) addition (An) or deletion (Dn) at the 59 end in
Tarbp2 2/2 whole embryos at E15.5 and their fold-
changes by counts per million (cpm) using RNA-seq.
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In an attempt to pharmacologically strengthen our find-
ings, we assessed the effect of enoxacin onMEFs derived from
Tarbp2 2/2 and Prkra 2/2 mutant embryos. Enoxacin has
been previously reported to inhibit the growth of cancer cells
by enhancing miRNA processing through a direct physical
interaction with TARBP2 miRNA (Shan et al. 2008; Melo
et al. 2011; Cornaz-Buros et al. 2014). If TARBP2 and PRKRA
are redundant, then cells expressing either of these proteins
should have a similar response to enoxacin treatment. If
enoxacin acts only through TARBP2, then Tarbp2 2/2, but
not Prkra 2/2, mutant MEFs should be resistant to its effects.
We initially found that the growth of transformed Tarbp2 2/2
MEFs was more sensitive to enoxacin than Prkra 2/2 MEFs,
supporting the possibility that enoxacin may act through
TARBP2. However, molecular analysis failed to reveal an in-
crease in miRNA levels in any genotype, and the changes that
were observed were the opposite of what has been observed
in cancer cells. Based on these observations, we conclude that
the growth effects of enoxacin on transformed MEFs are in-
dependent of TARBP2 or PRKRA and that enoxacin may act
through amechanism in transformedMEFs that is different to
that in cancer cells.
The discordant phenotypes betweenDicer and Tarbp2mu-
tants, and the observation that only a subset of miRNAs are
affected in Tarbp2 mutants, suggest that DICER does not re-
quire a cofactor for processing some pre-miRNAs or that an-
other as yet unidentified cofactor of DICER functions in early
embryogenesis. It has recently been shown that DICER inter-
acts with ADAR and lack of this association in Adar1mutants
impacts the biogenesis of mature miRNAs at E11.5 (Ota et al.
2013). These combined results suggest that DICER interacts
with different dsRBPs in canonical miRNA biogenesis during
Figure 3 Prkra is not required for
canonical microRNA (miRNA) bio-
genesis at embryonic day (E)15.5:
(A) Fold-change of overall expres-
sion of 3p and 5p miRNA tran-
scripts in C57Bl6 Prkra 2/2 whole
embryos at E15.5 compared to
wild-type embryos. (B) Plot of 3p
arm miRNA transcripts with one,
two, or three nucleotide (n = 1,
2, or 3) addition (An) or deletion
(Dn) at the 59 end in Prkra 2/2
whole embryos at E15.5 and their
fold-changes by counts per million
(cpm) using RNA-sequencing. (C)
A table chart summarizing the
type of deregulation and number of
miRNAs in Tarbp2 2/2 and Prkra 2/2
compared to wild-type. (D) Chart of
percent reads of miRNAs vs. other
small noncoding RNAs in the RNA-
sequencing libraries per genotype
and background. P2/2, Prkra 2/2;
T2/2, Tarbp2 2/2; WT, wild-type.
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embryonic development and that this association is specific to
developmental stage. DICER may also perform a function in
early embryogenesis that is independent of miRNA biogene-
sis, as has been previously suggested (Johanson et al. 2013).
The failure to detect defects in miRNA biogenesis in Prkra
mutants at E15.5, and the discordant phenotypes between
Dicer single mutants and Tarbp2 2/2; Prkra 2/2 double mu-
tants, suggests that the double-mutant phenotype is not
solely due to defects in miRNA biogenesis. The severity of
the phenotype in Tarbp2 2/2; Prkra 2/2 double-mutant em-
bryos could be due to the combination of defects in miRNA
biogenesis, as a consequence of the absence of TARBP2, cou-
pled with defects in endo-siRNA (small interfering RNA) bio-
genesis as a consequence of the absence of PRKRA. That
said, deletion of Dicer failed to affect the ability of siRNAs
to repress gene expression in murine embryonic stem cells
(Murchison et al. 2005). Alternatively, TARBP2 and PRKRA
could be functioning in a shared pathway that is independent
of DICER-mediated pre-miRNA processing. TARBP2 has been
shown to act independently of DICER to destabilize dsRNA
(Goodarzi et al. 2014), while PRKRA regulates translation by
activating PKR (Daniels and Gatignol 2012), a global regula-
tor of translation. The absence of both proteins could result in
increased levels of dsRNA, hyper-activation of PKR, and loss
of global control of translation leading to broad inhibition of
development.
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Figure 4 Enoxacin has its effect
on transformed mouse embryonic
fibroblasts (MEFs) independent of
Tarbp2 or Prkra: (A) Immunoblot
for TARBP2 and PRKRA shows
the expression or absence of these
proteins based on their genotype
in transformed MEFs. (B) Graphical
representation of cell numbers for
the indicated genotype after
enoxacin treatment from day 0 to
day 5. Relative units are obtained
after normalizing the cell numbers
from enoxacin treatment to the
cell numbers with DMSO treatment
(* P, 0.05 and ** P, 0.005). (B)
Expression fold-change of 10 quan-
tified mature microRNAs (miRNAs)
in transformedMEF cell lines with the
indicated genotype upon enoxacin
treatment (* P , 0.05 and ** P ,
0.005).
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